Subscribe for the Emerj "AI in Life Sciences Pulse" Newsletter

According to research from the American Society for Biochemistry and Molecular Biology, nine out of 10 drugs fail to make it to market in the clinical trials process. Researchers in the cited studies found that 40-50% of these failures are due to a lack of clinical efficacy, meaning that the drug is not able to produce its intended effect in people, and 30% were due to unmanageable toxicity or side effects.

Far beyond surface-level 'chatbot' software, and other customer-facing support systems, the same generative AI (GenAI) capabilities having direct impacts across language workflows in front-office tasks in financial and legal services is also having a direct impact on how research teams in the life sciences space are targeting solutions for rare diseases and novel treatments. 

This interview analysis is sponsored by Deloitte and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

This interview analysis is sponsored by Deloitte and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

This interview analysis is sponsored by Quantiphi and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.